Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company.
He also held various executive positions with Life Technologies, Inc.(now Thermo Fisher Scientific) that included leading its global businesses, mergers and acquisitions and its initial public offering (“IPO”). Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization.
Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.
Mr. Holtz serves as MaxCyte’s Chief Financial Officer (CFO), having joined the Company in 2005. Previously, he has been CFO of both public and private companies and has raised more than $100 million in debt and equity capital. He also had previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.
Dr. Dansky Ullmann, a 25+-year expert in clinical oncology and pharmaceutical research, is responsible for overseeing clinical development of MaxCyte’s CARMA™ drug development program. Dr. Dansky Ullmann was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where, as part of the executive leadership team, he oversaw all clinical development and operations, shaped corporate strategy, and was directly involved in business development activities as well as investor and analyst interactions. Previously, he was a senior medical director and global clinical lead for oncology clinical research in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before joining Takeda, Dr. Dansky Ullmann worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) as a senior investigator participating in numerous early-phase and late-phase clinical trials. During his career, he also held research roles at the National Institute of Health and held postdoctoral fellowship positions in tumour immunotherapy and drug resistance at the NCI. He also was involved in the development of cell therapies and other immunotherapies at Biomira, Inc. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, University of Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.
Ms. Abbato serves as MaxCyte’s Executive Vice President, Business Development for CARMA Cellular Therapies, where she is responsible for building and growing MaxCyte’s CARMA cell therapy business by leading the strategic planning and execution of all business development activities related to the CARMA-based platform. Before joining MaxCyte, Ms. Abbato served as Vice President of Business Development at Celdara Medical, where she was responsible for all out-licensing and exit-related transactions and product planning activities. Previously, she was Principal and Owner of Perspicere, providing business development, strategy, and planning services to biotechnology companies. Prior, Ms. Abbato was responsible for search and evaluation, in- and out-licensing transactions, merger and acquisition, and spin-out activities at Human Genome Sciences for 12 years. She holds an MBA from the University of Pittsburgh and a BS in Chemical Engineering and Biochemistry from the University of Maryland, College Park.
Mr. Calvin is a 25-year veteran within the diagnostics, devices, drug discovery and life sciences industries. In his role as MaxCyte’s EVP of Global Commercial Operations, he is responsible for leading the Company’s sales, marketing and business development functions to define product strategy, deliver new products and drive growth of its drug discovery and cell therapy businesses. Mr. Calvin was most recently Co-founder and President of AsedaSciences, a company with an integrated technology platform to predict in vivo toxicity risk in early-stage drug discovery. Previously, he has held various global and regional leadership positions at companies ranging from large corporations to start-ups, such as Accuvein, Beckman Coulter, Qiagen, Digene, AGENIX, and Abbott Laboratories. He has a Bachelor’s degree in Applied Science from Curtin Institute of Technology in Perth, Western Australia.
Mr. Ross serves as MaxCyte’s Executive Vice President of Global Sales, having joined the Company in 2014. Mr. Ross has extensive experience in all elements of commercial operations and has more than 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. Mr. Ross also served as Chief Commercial Officer at Predictive BioScience and Vice President of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, he held several senior leadership roles in Manufacturing Operations at Life Technologies, Inc. and Cambrex. Mr. Ross has a Bachelor’s of Business Administration from The Citadel.
Mr. Masoud brings to MaxCyte 12 years of experience as an attorney and general counsel in the biotech industry. He has served as Assistant General Counsel and Corporate Secretary for Wellstat Management Company; co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors; and Corporate Attorney at Human Genome Sciences, Inc. Mr. Masoud managed the legal team on the launch of two FDA-approved drugs while at Wellstat. At Human Genome Sciences, he assisted with FDA compliance for the product launch of Benlysta®, negotiated and executed more than 1,000 clinical trial agreements, negotiated licensing deals valued at over $300 million, and assisted the company with raising financing through bond and secondary stock offerings in excess of $800 million. A member of the Maryland State Bar, Mr. Masoud holds a JD from Michigan State University College of Law, and a BS in Cell & Molecular Biology Genetics from the University of Maryland.
Dr. Brady is Vice President of Technical Applications and Customer Support at MaxCyte, Inc. Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Previously, he worked at MetaMorphix, Inc. as a Group Leader in the Company’s Transgenic Livestock program, and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a Bachelor of Science degree in biology from the College of William and Mary, a Ph.D. in genetics from Indiana University and an MBA from Johns Hopkins University.
Dr. Chinnasamy, a 20+-year expert in the research and translation of gene and immunotherapies, oversees all non-clinical and translational activities for MaxCyte’s CARMA platform working closely with the clinical, regulatory, manufacturing, and business development teams in support of MaxCyte’s clinical-stage therapeutic development. Her vast experience includes key roles in bench-to-bedside translational studies on T and NK cell-based therapeutics for the treatment of cancer. Most recently, she led the immuno-oncology team at Precigen/Intrexon where she developed novel T cell products co-expressing chimeric antigen receptors (CARs) and cytokine genes targeting solid tumors. Previously, she served as a Senior Staff Scientist in the Hematology Branch at the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH), and as a Senior Research Fellow in the Surgery Branch of the NIH’s National Cancer Institute (NCI). Dr. Chinnasamy holds a PhD in botany from Bharathiar University, India, an MS in integrated biology from Madurai Kamaraj University, India, and a BS in zoology from University of Madras, India.
Dr. Wekselman is a senior drug development expert with extensive experience in drug development, clinical protocol development and execution, and interactions with regulatory authorities, including leading or developing marketing application submissions to the U.S. Food and Drug Administration (FDA), the European Medicines Agency and Health Canada for drugs, biologics and medical devices. She has 11 years of clinical research organization experience as a consultant to pharmaceutical, biotechnology, and device companies, and nine years at Procter & Gamble Pharmaceuticals, where she held positions in medical writing, medical monitoring, and project leadership. Dr. Wekselman earned her BSN (summa cum laude) and PhD in nursing from the University of Cincinnati. She had 10 years of clinical and academic experience in nursing before joining the industry to work in drug development. She has authored more than 25 journal articles or book chapters and has presented more than 30 posters, conference sessions, guest lectures and professional education seminars.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter